Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleInflammation, Immunopharmacology, and Asthma

Methoxyluteolin Inhibits Neuropeptide-stimulated Proinflammatory Mediator Release via mTOR Activation from Human Mast Cells

Arti B. Patel and Theoharis C. Theoharides
Journal of Pharmacology and Experimental Therapeutics June 2017, 361 (3) 462-471; DOI: https://doi.org/10.1124/jpet.117.240564
Arti B. Patel
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, Massachusetts (A.B.P. and T.C.T.); Graduate Program in Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts (A.B.P.); Departments of Internal Medicine and Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts (T.C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theoharis C. Theoharides
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, Massachusetts (A.B.P. and T.C.T.); Graduate Program in Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts (A.B.P.); Departments of Internal Medicine and Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts (T.C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Inhibitors of mTOR signaling dose-dependently decrease SP-stimulated proinflammatory mediator release from human MCs. (A and B) LAD2 MCs (0.5 × 106 cells) were pretreated with the mTOR inhibitor rapamycin (0.05–0.2 µM, 24 hours) or the ATP-competitive mTOR inhibitor Torin1 (0.05–0.2 µM, 24 hours) prior to stimulation with SP (1 μM) for 24 hours to measure release of TNF (A) and CXCL8 (B) by ELISA. (C) LAD2 MCs (0.5 × 106 cells) were also pretreated with the upstream PI3K inhibitor LY294002 (1–10 µM, 2 hours) prior to stimulation with SP (1 μM) for 24 hours to measure release of TNF and CXCL8 mediators. All inhibitors were dissolved in water or DMSO with a final concentration of <0.1%. All conditions were performed in triplicate for each data set and were repeated three times. Results are presented as means ± S.D. Significance of comparisons was assessed for stimulated cells without any inhibitor (control) and for those with an inhibitor/flavonoid, as denoted by the horizontal lines that indicate significance at P < 0.001 for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves, and the vertical brackets indicate the corresponding levels of significance when present (*P < 0.05; **P < 0.001; ***P < 0.0001).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Human MC proinflammatory mediator release in response to NT or SP is attenuated by PI3K/mTOR inhibitors and the flavonoids luteolin and methoxyluteolin. (A–F) LAD2 MCs (0.5 × 106 cells) were pretreated with the mTOR inhibitors rapamycin (Rap) and Torin1 (0.2 µM, 24 hours), the upstream PI3K inhibitor LY294002 (LY; 10 µM, 2 hours), or the natural flavonoids luteolin (Lut) and methoxyluteolin (Methlut; 50 µM, 30 minutes) and then stimulated with NT (10 μM) (A–C) or the positive control trigger SP (1 μM) (D–F) for 24 hours to measure release of TNF, CXCL8, and VEGF mediators by specific ELISAs. All conditions were performed in triplicate for each data set and were repeated three times, with results presented as means ± S.D. Significance of comparisons was assessed for stimulated cells without any inhibitor (control) and for those with an inhibitor/flavonoid, as denoted by the horizontal lines that indicate significance at P < 0.0001 for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves, and the horizontal brackets indicate the corresponding levels of significance when present (*P < 0.05; **P < 0.001; ***P < 0.0001).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Human LAD2 MC proinflammatory mediator gene expression in response to NT or SP is inhibited by the PI3K/mTOR inhibitors luteolin and methoxyluteolin. (A–F) LAD2 MCs (1 × 106 cells) were pretreated with the mTOR inhibitors rapamycin (Rap) and Torin1 (0.2 µM, 2 or 24 hours), the upstream PI3K inhibitor LY294002 (LY; 10 µM, 2 hours), or the natural flavonoids luteolin (Lut) and methoxyluteolin (Methlut; 50 µM, 30 minutes) prior to stimulation with NT (10 μM) (A–C) or the positive control trigger SP (1 μM) (D–F) for 6 hours to measure gene expression of TNF, CXCL8, and VEGF by quantitative real-time polymerase chain reaction. All inhibitors were dissolved in water or DMSO with a final concentration of <0.1%. All conditions were performed in triplicate for each data set and were repeated three times, with results presented as means ± S.D. Significance of comparisons was assessed for stimulated cells without any inhibitor (control) and for those with inhibitor/flavonoid, as denoted by the horizontal lines that indicate significance at P < 0.0001 for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves, and the horizontal brackets indicate the corresponding levels of significance when present (*P < 0.05; **P < 0.001; ***P < 0.0001).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    NT and SP stimulate mTOR activation in human LAD2 MCs. (A–F) LAD2 MCs (1 × 106 cells) were stimulated with NT (10 µM) (A–C) or the positive control trigger SP (1 μM) (D–F) for 0–60 minutes to probe for the total and phosphorylated levels of mTOR and substrates p70S6K and 4EBP1 by Western blot analysis. Peak mTOR activation was denoted at 20 minutes for pmTORSer2448 and pp70S6KThr389 proteins, whereas the levels of p4EBP1Thr37/46 protein remained unchanged. Results were quantified using densitometric analyses for pmTORSer2448 to mTOR levels (B and D) and pp70S6KThr389 to p70S6K levels (B and E) in response to NT (10 µM) or SP (1 μM). All conditions were performed in triplicate for each data set and were repeated three times, with results presented as means ± S.D. Significance of comparisons was assessed for unstimulated cells without NT or SP treatment and for those stimulated by the neuropeptides (*P < 0.05; **P < 0.001; ***P < 0.0001).

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    NT- or SP-stimulated mTOR activation in LAD2 MCs is inhibitable by luteolin and methoxyluteolin. (A–F) LAD2 MCs (1 × 106 cells) were pretreated with the mTOR inhibitors rapamycin (Rap) and Torin1 (0.2 µM, 24 hours), the upstream PI3K inhibitor LY294002 (LY; 10 µM, 2 hours), or the natural flavonoids luteolin (Lut) and methoxyluteolin (Methlut; 10 or 50 µM, 30 minutes) prior to stimulation with NT (10 μM) (A–C) or SP (1 μM) (D–F) for 20 minutes to probe for the total and phosphorylated levels of mTOR and substrates p70S6K and 4EBP1 by both phospho-ELISA kits and Western blot analysis (lower image). The protein levels of mTOR and pmTOR Ser2448 (A and D) and the downstream mTORC1 substrates p70S6K and pp70S6K Thr389 (B and E) and 4EBP1 and p4EBP1 Thr37/46 (C and F) were measured using specific total or phospho-ELISA kits for equal amounts of protein lysates, with normalized ratios of phosphorylated to total proteins. All conditions were performed in triplicate for each data set and were repeated three times, with results presented as means ± S.D. Significance of comparisons was assessed for stimulated cells without any inhibitor (control) and for those with inhibitor/flavonoid, as denoted by the horizontal lines that indicate significance at P < 0.0001 for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves, and the horizontal brackets indicate the corresponding levels of significance when present (*P < 0.05; **P < 0.001; ***P < 0.0001).

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Figures -


      Supplementary Figure 1. Human MC degranulation in response to NT or SP is decreased by the PI3K inhibitor LY294002, luteolin and methoxyluteolin.  


      Supplementary Figure 2. Methoxyluteolin more potently than luteolin inhibits NT-stimulated pro-inflammatory mediator release from human MC.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 361 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 361, Issue 3
1 Jun 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Methoxyluteolin Inhibits Neuropeptide-stimulated Proinflammatory Mediator Release via mTOR Activation from Human Mast Cells
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleInflammation, Immunopharmacology, and Asthma

Neuropeptide Stimulation of Human Mast Cells via mTOR

Arti B. Patel and Theoharis C. Theoharides
Journal of Pharmacology and Experimental Therapeutics June 1, 2017, 361 (3) 462-471; DOI: https://doi.org/10.1124/jpet.117.240564

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleInflammation, Immunopharmacology, and Asthma

Neuropeptide Stimulation of Human Mast Cells via mTOR

Arti B. Patel and Theoharis C. Theoharides
Journal of Pharmacology and Experimental Therapeutics June 1, 2017, 361 (3) 462-471; DOI: https://doi.org/10.1124/jpet.117.240564
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • All-trans retinoic acid inhibits migration and invasiveness of rheumatoid fibroblast-like synoviocytes
  • EP2/4 receptors promotes the synthesis of PGE2 increasing tissue damage in bovine endometrial explants induced by Escherichia coli
  • Role of RORγt in Interleukin-23–Mediated Skin Inflammation
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics